• Home
  • About Journal
    Journal Introduction
    Editorial Board
    Youth Editorial Board
    Cooperating Institutions
    Editorial Department
  • Submission Guidelines
  • Policies & Statements
    Ethical Guidelines for Publication
    Academic Misconduct Statement
    Open Access (OA) Statement
    AIGC Use Statement
  • Journal Subscription
  • Download Center
  • 中文版
Cite this article:
WANG Bing,WANG Yuting,HUANG Huixuan,TANG Huaying,CUI Yingjie,LI Yuhui,LENG Jiawei.Real world study and comprehensive clinical evaluation of bevacizumab second-line treatment for non squamous non-small cell lung cancer[J].Journal Of Pharmaceutical Research,2026,45(6):700-705,715[Click to copy]
【Print this page】      【Download PDF Full Text】   【View/Add Comment】  【Download reader】  【 Close 】
←Previous|Next→ Archive    Advanced Search
This article has been viewed: 1251times   Download 623次 QR Code for this article
Scan with your phone!
贝伐珠单抗二线治疗非鳞非小细胞肺癌的真实世界研究与临床综合评价
王冰1,王雨廷1,黄慧选2,汤华颖1,崔瑛洁1,李渝慧1,冷佳蔚3
Font:Larger+|Default|Smaller-
(1.山东大学附属威海市立医院药剂科,山东 威海 264200;2.山东大学附属威海市立医院护理部,山东 威海 264200;3.山东省食品药品检验研究院,山东 济南 250101)
摘要:
目的 基于真实世界临床数据,比较贝伐珠单抗原研药(安维汀)与生物类似药(安可达)二线治疗非鳞非小细胞肺癌的有效性和安全性,为临床用药选择提供参考。方法 回顾性分析2019年1月1日至2021年1月31日山东大学附属威海市立医院收治的82 例接受贝伐珠单抗注射液(安维汀)或(安可达)的IV期非鳞非小细胞肺癌患者的病历资料,采用Kaplan-Meier法进行单因素生存分析、采用χ2 检验进行安维汀组及安可达组临床及治疗特征比较、近期疗效及不良反应比较、Log-rank检验进行组间差异比较、Cox回归法进行多因素预后分析。结果 2年OS为63.3%,2年PFS为60.0%。安维汀组:ORR为33.3%,DCR为87.5%;安可达组:ORR为27.6%,DCR为96.6%。两组的DCR(疾病控制率)和ORR(客观缓解率)差异无统计学意义(P=0.147*;χ2 =0.271,P=0.603)。安维汀组较安可达组PFS(χ2 =0.022,P=0.883)和OS(χ2 =0.041,P=0.840)差异均无统计学意义。两组临床及治疗特征均未显示安维汀组优于安可达组。两组不良反应差异无统计学意义(P>0.05)。Cox法多因素分析显示:未脑转移是影响OS(HR=0.446,P=0.042)的独立保护因素。结论 安维汀组较安可达组DCR、ORR、PFS、OS和不良反应差异均无统计学意义。未脑转移是影响OS(HR=0.446,P=0.042)的独立保护因素。
关键词:  非鳞非小细胞肺癌  安维汀  安可达  不良反应
DOI:10.13506/j.cnki.jpr.2026.06.014
基金项目:2021年度山东省医学会临床科研资金项目(No.YXH2022ZX02054)
Received Date:March 20, 2026   Revision Date:April 14, 2026  
Real world study and comprehensive clinical evaluation of bevacizumab second-line treatment for non squamous non-small cell lung cancer
WANG Bing1,WANG Yuting1,HUANG Huixuan2,TANG Huaying1,CUI Yingjie1,LI Yuhui1,LENG Jiawei3
(1.Department of Pharmacy,Weihai Municipal Hospital, Cheeloo College of Medicine, Shandong University, Weihai 264200, China;2.Nursing Department,Weihai Municipal Hospital, Cheeloo College of Medicine, Shandong University, Weihai 264200,China;3.Shandong Institute for Food and Drug Inspection and Research,Jinan 250101,China)
Abstract:
Objective To compare the efficacy and safety of the original bevacizumab (Avastin) and its biosimilar (Ankeda) in the second-line treatment of non-squamous non-small cell lung cancer (NSCLC) based on real-world clinical data, and to provide evidence for clinical decision-making.Methods The clinical data of 82 patients with non-squamous non-small cell lung cancer who received bevacizumab injection (Avastin) or (Ankeda) in Weihai Municipal Hospital Affiliated to Shandong University from January 1, 2019 to January 31, 2021 were retrospectively analyzed. Kaplan-Meier method was used for univariate survival analysis, χ2 test was used to compare the clinical and treatment characteristics, short-term efficacy and adverse reactions between the two groups, Log-rank test was used to compare the differences between the two groups, and Cox regression method was used for multivariate prognostic analysis.Results The 2-year OS and PFS were 63.3% and 60.0%, respectively. In the Avastin group: ORR was 33.3%, DCR was 87.5%; In the Anketa group, ORR was 27.6% and DCR was 96.6%. There was no significant difference in DCR (disease control rate) and ORR (objective response rate) between the two groups (P=0.147*; χ2=0.271, P=0.603). There were no significant differences in PFS (χ2=0.022, P=0.883) and OS (χ2=0.041, P=0.840) between Avastin group and Anketa group. The clinical and treatment characteristics of the two groups did not show that the Avastin group was superior to the Anketa group. There was no significant difference in adverse reactions between the two groups (P>0.05). Cox multivariate analysis showed that no brain metastasis was an independent protective factor for OS (HR=0.446, P=0.042).Conclusion There were no significant differences in DCR, ORR, PFS and OS between the two groups. There was no significant difference in adverse reactions between the two groups.No brain metastasis was an independent protective factor for OS.
Key words:  Non-squamous non-small cell lung cancer  Avastin  Ankeda  Adverse reactions
Today's Visits:447    Total Visits:2383131
Website copyright:Editorial Board of Journal of Pharmaceutical Research     鲁ICP备17018036号-3     鲁公网安备 37010202001351号
Sponsored by:Shandong Institute for Food and Drug Control Shandong Pharmaceutical Association Address:No.2749 Xinluo Street,High-Tech Zone,Jinan,P.R.China Postcode:250101
Telephone Number:0531-81216586 Email :yaoxueyanjiu@163.com;yaoxueyanjiu@126.com
Technical Support:Beijing Qinyun Technology Co., Ltd.